Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

las Venture, Sanderling Ventures, CDC Innovation, and Ventech. Xytis has a rich portfolio of proprietary preclinical compounds that are novel, highly selective allosteric modulators of nicotinic acetylcholine receptors (nAChRs), GABA-A receptors and other well-validated CNS targets. The Company has two compounds in clinical development -- Neboglamine (XY2401) and Anatibant (XY2405). Neboglamine is a selective norepinephrine uptake inhibitor, which has completed single and multiple dose Phase 1 studies, and is intended for the treatment of patients with schizophrenia and/or major depression. XY2401 has been well tolerated in the Phase 1 studies. Anatibant (XY2405), Xytis' lead compound, is under development for TBI with a Phase 2 multi-center trial ongoing in nine countries worldwide with more than 200 patients enrolled. See http://www.xytis.com for additional information.


'/>"/>
SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)....Y., Jan. 6 In recent controlled s...ty of Memphis , scientists found that the patented... first and only proven ingredient to increase leve...asing blood nitrate/nitrate (NOx) in human subject...nables an increase in blood flow to the skeletal m...
(Date:1/6/2009)...PANY, N.J., Jan. 6 Pacira Pharmace...ical company, announced today that enrollment,has...ials to evaluate the,safety and efficacy of a sin...(DepoBupivacaine) for prolonged postoperative anal...hoidectomy and in total knee,arthroplasty (TKA) a...
(Date:1/5/2009)...SE, Calif., Jan. 5 Women undergoin...ne medication to help support early,pregnancy, bu...his medication,can be painful for patients. Form...administered by subcutaneous injection or vaginal ... patient tolerance. , With patient well-bei...
(Date:12/27/2008)...S, Bermuda, Dec. 23 Warn...day that one of its subsidiaries and Mayne Pharma ... Hospira, Inc., have filed lawsuits against each o...Mylan Pharmaceuticals Inc. ("Mylan") and Impax Lab...or the District of New Jersey for infringement of ...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 1NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 2NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 4NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 5NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 6UC San Diego researchers target tumors with tiny nanoworms 18615 1UC San Diego researchers target tumors with tiny nanoworms 18615 2UC San Diego researchers target tumors with tiny nanoworms 18615 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 1Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 2Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 4Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 1Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 2
... to Company Oncology Programs to be Presented, SOU...re-FirstCall/ -- Cytokinetics, Incorporated announ...l data will be,presented at the 2007 Annual Meetin...(AACR) to be held from April 14- 18, 2007 in,Los A...oncology,programs at Cytokinetics and will present...
...a.--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline...:ADLR) today announced data from Study 767905/014 ... program for,alvimopan (Entereg/Entrareg(R))., Stu...d (12,month) study, was designed to evaluate the l...mg twice daily in patients taking,opioids for chro...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:1/8/2009)...embly Member Tom Torlakson Introduces AB 89 , ,.../ -- Today, Lung Cancer Alliance-California (LCA...son (D-11th District) for his continued leadership...lung cancer research. For the third consecutive y...rch is being considered in the California Legislat...
(Date:1/8/2009)...ered bad cholesterol more effectively than Zocor ,...After nearly a year of review, U.S. health officia... use of the controversial cholesterol-lowering dru...ion said there was no significant difference in ca...orin and patients taking the drug Zocor. , But,...
(Date:1/8/2009)...d Acquisition in 2009 Continues Growth Trend , ,...tCall/ -- IPC The Hospitalist Company, Inc. (Nasda...ian group practice company, announced today that i... Acute Care Consultants, Inc. (MACC) in St. Louis,...pansion in the St. Louis market, where IPC has est...
(Date:1/8/2009)...d when assessing traditional risk factors, experts...s) -- Two molecular signs -- or "biomarkers" -- of...trying to assess a person,s risk of stroke, new re...w risk, adding these markers does not change thing... cardiologist at the Methodist DeBakey Heart &...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3
...o a new study shows that women with a specific ge...esterol when they take oestrogen.// Previous resea...) might protect women from heart disease. Now doct...ed a strong genetic influence in how a woman's cho...
...an psychiatrist has discovered that treating patie...lusions and halucinations.// Although antipsychoti...any people still suffer these. But researchers ha...rogen can help protect against schizophrenia, beca...
...o study in University of Texas, a novel blood test...ing a possible new way to predict who might get Al...icine in St. Louis said it is unclear whether a si..., but the findings in the animal studies appeared ...
...d Drug Administration announced that Vioxx - Merck...mation on its label. The FDA said that Merck can c...ations// than one older non-steroidal anti-inflamm...at the Vioxx label must mention that it might be l...
Other Medicine News:Health News:Blood test may aid foretell Alzheimer's 2
...ct Complete® is a scientifically advanced nutr...ion for macular and full body health. MacularProte...nd other advanced research. It features a comprehe...d foundation of antioxidants, such as 10 mg of Flo...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc,
Most people take their eyes for granted. Like the rest of your body, your eyes need proper nutrition and care to help maintain eye health and vision as you age. In fact, research indicates proper nut
Medicine Products: